ATE365206T1 - Verfahren zur entwicklung von einem hiv impfstoff - Google Patents
Verfahren zur entwicklung von einem hiv impfstoffInfo
- Publication number
- ATE365206T1 ATE365206T1 AT99932507T AT99932507T ATE365206T1 AT E365206 T1 ATE365206 T1 AT E365206T1 AT 99932507 T AT99932507 T AT 99932507T AT 99932507 T AT99932507 T AT 99932507T AT E365206 T1 ATE365206 T1 AT E365206T1
- Authority
- AT
- Austria
- Prior art keywords
- hiv
- immune response
- developing
- hiv vaccine
- inactivated
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title 1
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 4
- 230000028993 immune response Effects 0.000 abstract 3
- 102100034343 Integrase Human genes 0.000 abstract 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16061—Methods of inactivation or attenuation
- C12N2740/16063—Methods of inactivation or attenuation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7464698P | 1998-02-13 | 1998-02-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE365206T1 true ATE365206T1 (de) | 2007-07-15 |
Family
ID=22120781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99932507T ATE365206T1 (de) | 1998-02-13 | 1999-02-12 | Verfahren zur entwicklung von einem hiv impfstoff |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US6383806B1 (de) |
| EP (1) | EP1056838B1 (de) |
| AT (1) | ATE365206T1 (de) |
| AU (1) | AU764938B2 (de) |
| CA (1) | CA2323011C (de) |
| DE (1) | DE69936337T2 (de) |
| WO (1) | WO1999041360A1 (de) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6232494B1 (en) | 1998-02-12 | 2001-05-15 | Monsanto Company | Process for the preparation of N-(phosphonomethyl)glycine by oxidizing N-substituted N-(phosphonomethyl)glycine |
| US6503753B1 (en) * | 1998-02-13 | 2003-01-07 | Adan Rios | Method for the development of an HIV vaccine |
| US9974847B2 (en) * | 2000-08-24 | 2018-05-22 | Immunitor USA, Inc. | Treatment and prevention of tuberculosis |
| US20030092145A1 (en) * | 2000-08-24 | 2003-05-15 | Vic Jira | Viral vaccine composition, process, and methods of use |
| US20040236093A1 (en) * | 2001-02-27 | 2004-11-25 | Olivier Schwartz | Mhc-i-restricted presentation of hiv-1 virion antigens without viral replication. application to the stimulation of ctl and vaccination in vivo; analysis of vaccinating composition in vitro |
| US7786288B2 (en) * | 2003-10-23 | 2010-08-31 | Karp Nelson M | Immunizing compositions encoding an epitope obtained from the HIV-1 capsid protein cyclophilin A binding site |
| WO2008054481A2 (en) | 2006-03-24 | 2008-05-08 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health | Improved inactivated influenza virus compositions |
| US8613934B2 (en) | 2004-03-22 | 2013-12-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cellular and viral inactivation |
| AU2005227320B2 (en) * | 2004-03-22 | 2010-06-24 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, National Insitutes Of Health | Cellular and viral inactivation |
| KR100568542B1 (ko) * | 2004-08-19 | 2006-04-07 | 삼성전자주식회사 | 자기 램 소자의 기록방법 |
| EP1797175B1 (de) * | 2004-10-04 | 2008-07-16 | Biovaxim Limited | Subtypabgestimmte inaktivierte vollvirusvakzine zur behandlung von patienten mit hiv-infektion |
| KR101701198B1 (ko) | 2008-06-19 | 2017-02-01 | 배리에이션 바이오테크놀로지스 아이엔씨. | 인플루엔자를 치료하기 위한 조성물 및 방법 |
| CA2803282C (en) | 2009-07-06 | 2018-05-01 | David E. Anderson | Methods for preparing vesicles and formulations produced therefrom |
| BR112012000826B1 (pt) | 2009-07-06 | 2022-07-26 | Variation Biotechnologies Inc | Método para a preparação de vesículas |
| US8367315B2 (en) * | 2010-03-05 | 2013-02-05 | Adan Rios | Inactivation of reverse transcriptases by azido-diarylpyrimidines |
| WO2012006367A2 (en) | 2010-07-06 | 2012-01-12 | Variation Biotechnologies, Inc. | Compositions and methods for treating influenza |
| CA2862864C (en) | 2011-01-13 | 2018-12-11 | Variation Biotechnologies Inc. | Compositions and methods for treating viral infections |
| EP2802353A4 (de) | 2012-01-12 | 2015-12-02 | Variation Biotechnologies Inc | Zusammensetzungen und verfahren zur behandlung von virusinfektionen |
| CN104244984B (zh) | 2012-01-27 | 2020-03-31 | 变异生物技术公司 | 用于治疗剂的方法和组合物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5256767A (en) | 1987-06-10 | 1993-10-26 | The Immune Response Corporation | Retroviral antigens |
| US5861282A (en) | 1989-10-16 | 1999-01-19 | Whitehead Institute For Biomedical Research | Non-infectious HIV particles and uses therefor |
| US5912338A (en) | 1990-10-12 | 1999-06-15 | Benjamin Rovinski | Nucleic acids encoding self-assembled, non-infectious, non-replicating, immunogenic retrovirus-like particles comprising modified HIV genomes and chimeric envelope glycoproteins |
| US6080408A (en) | 1994-08-22 | 2000-06-27 | Connaught Laboratories Limited | Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles |
-
1999
- 1999-02-12 AT AT99932507T patent/ATE365206T1/de not_active IP Right Cessation
- 1999-02-12 EP EP99932507A patent/EP1056838B1/de not_active Expired - Lifetime
- 1999-02-12 CA CA2323011A patent/CA2323011C/en not_active Expired - Lifetime
- 1999-02-12 WO PCT/US1999/003217 patent/WO1999041360A1/en not_active Ceased
- 1999-02-12 AU AU32937/99A patent/AU764938B2/en not_active Ceased
- 1999-02-12 DE DE69936337T patent/DE69936337T2/de not_active Expired - Lifetime
- 1999-02-12 US US09/249,391 patent/US6383806B1/en not_active Expired - Lifetime
-
2002
- 2002-05-06 US US10/140,356 patent/US6653130B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE69936337D1 (de) | 2007-08-02 |
| DE69936337T2 (de) | 2008-02-21 |
| WO1999041360A1 (en) | 1999-08-19 |
| US6653130B2 (en) | 2003-11-25 |
| AU764938B2 (en) | 2003-09-04 |
| CA2323011A1 (en) | 1999-08-19 |
| CA2323011C (en) | 2013-01-15 |
| AU3293799A (en) | 1999-08-30 |
| US20030129200A1 (en) | 2003-07-10 |
| EP1056838B1 (de) | 2007-06-20 |
| EP1056838A1 (de) | 2000-12-06 |
| US6383806B1 (en) | 2002-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69936337D1 (de) | Verfahren zur entwicklung von einem hiv impfstoff | |
| DE60226911D1 (de) | Entwicklung einer Vakzine zur Prävention von Infektionen mit Filovirus bei Primaten | |
| DK0584348T3 (da) | Genetisk vaccine mod immundefektvirusser | |
| ES2187530T3 (es) | Peptidos para reducir respuestas de linfocito t ctitotoxicos al virus de la hepatitis b. | |
| CY1106785T1 (el) | Ιικα σωματιδια τα οποια απελευθερωνονται μετα απο μολυνση απο ανθρωπινο κυτταρομεγαλοϊο και η χρηση τους ως εμβολιο | |
| DE60144240D1 (de) | Zusammensetzung mit immunogenen mikroteilchen | |
| DE69933433D1 (de) | Virus enthaltende zusammensetzungen und methoden zur konzentration von viruspräparaten | |
| ATE426412T1 (de) | Adjuvante influenza-vakzine | |
| TW377373B (en) | Recombinant raccoon pox viruses and their use as an effective vaccine against feline infectious peritonitis virus disease | |
| DK1542732T3 (da) | Fusionsproteiner af Mycobacterium tuberculosis | |
| DK0534618T3 (da) | Peptider til fremkaldelse af cytotoksiske T-lymfocytreaktioner mod hepatitis B-virus | |
| AR004464A1 (es) | Un metodo para producir una proteina de capside de papilomavirus | |
| AU6302280A (en) | Feline infectious peritonitis vaccine | |
| CO5280138A1 (es) | Virus atenuados e inocuos de la diarrea virica bovina para en vacas gestantes | |
| EA200301151A1 (ru) | Вакцина против натуральной оспы | |
| DE60231821D1 (de) | Rekombinante tollwut-vakzine und verfahren zu ihrer herstellung und verwendung | |
| DE60239753D1 (de) | Impfstoff gegen infektiöses lachsanämievirus | |
| ATE401392T1 (de) | Subtypabgestimmte inaktivierte vollvirusvakzine zur behandlung von patienten mit hiv-infektion | |
| AU5573196A (en) | A pluripotent vaccine against enveloped viruses | |
| DE68920345D1 (de) | Lebendes Kombinationsvakzin. | |
| DE69428984D1 (de) | Stimulierung der immunantwort durch virales protein | |
| SE9202934D0 (sv) | Vacciner mot melanom | |
| ES2055610T3 (es) | Vacuna contra hrsv. | |
| PT100460A (pt) | Partiiculas derivadas de virus de herpes e vacinas que as contem | |
| NZ510130A (en) | Chicken anaemia viruses of low pathogenicity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |